Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 84

1.

The dual role of TLR3 in metastatic cell line.

Matijevic T, Pavelic J.

Clin Exp Metastasis. 2011 Oct;28(7):701-12. doi: 10.1007/s10585-011-9402-z. Epub 2011 Jul 7.

PMID:
21735101
2.

The Toll-like receptor gene family is integrated into human DNA damage and p53 networks.

Menendez D, Shatz M, Azzam K, Garantziotis S, Fessler MB, Resnick MA.

PLoS Genet. 2011 Mar;7(3):e1001360. doi: 10.1371/journal.pgen.1001360. Epub 2011 Mar 31.

3.

Toll-like receptors in normal and malignant human bladders.

Ayari C, Bergeron A, LaRue H, Ménard C, Fradet Y.

J Urol. 2011 May;185(5):1915-21. doi: 10.1016/j.juro.2010.12.097. Epub 2011 Mar 21.

PMID:
21421234
4.

A Phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCGrefractory and BCG-intolerant patients.

Kowalski M, Entwistle J, Cizeau J, Niforos D, Loewen S, Chapman W, MacDonald GC.

Drug Des Devel Ther. 2010 Nov 15;4:313-20. doi: 10.2147/DDDT.S14071.

5.

The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study.

Proctor MJ, Talwar D, Balmar SM, O'Reilly DS, Foulis AK, Horgan PG, Morrison DS, McMillan DC.

Br J Cancer. 2010 Sep 7;103(6):870-6. doi: 10.1038/sj.bjc.6605855. Epub 2010 Aug 17.

6.

TLR stimulation of prostate tumor cells induces chemokine-mediated recruitment of specific immune cell types.

Galli R, Starace D, Busà R, Angelini DF, Paone A, De Cesaris P, Filippini A, Sette C, Battistini L, Ziparo E, Riccioli A.

J Immunol. 2010 Jun 15;184(12):6658-69. doi: 10.4049/jimmunol.0902401. Epub 2010 May 17.

7.

Targeting Toll-like receptors: emerging therapeutics?

Hennessy EJ, Parker AE, O'Neill LA.

Nat Rev Drug Discov. 2010 Apr;9(4):293-307. doi: 10.1038/nrd3203. Review.

PMID:
20380038
8.

Evolution on experimental animal model for upper urothelium carcinogenesis.

Reis LO, Fávaro WJ, Ferreira U, Billis A, Fazuoli MG, Cagnon VH.

World J Urol. 2010 Aug;28(4):499-505. doi: 10.1007/s00345-010-0545-3. Epub 2010 Apr 6.

PMID:
20373103
9.

Toll-like receptors: cost or benefit for cancer?

Matijevic T, Pavelic J.

Curr Pharm Des. 2010;16(9):1081-90. Review.

PMID:
20030618
10.
11.

Functionally active toll-like receptor 3 on human primary and metastatic cancer cells.

Matijevic T, Marjanovic M, Pavelic J.

Scand J Immunol. 2009 Jul;70(1):18-24. doi: 10.1111/j.1365-3083.2009.02262.x.

12.

A biotechnological product and its potential as a new immunomodulator for treatment of animal phlebovirus infection: Punta Toro virus.

Durán N, Gowen BB, Costa FT, Justo GZ, Brocchi M, Nunes OS, Nunes IS.

Antiviral Res. 2009 Aug;83(2):143-7. doi: 10.1016/j.antiviral.2009.04.006. Epub 2009 Apr 22.

PMID:
19393266
13.

Experimental animal model and RNA interference: a promising association for bladder cancer research.

Reis LO, Pereira TC, Favaro WJ, Cagnon VH, Lopes-Cendes I, Ferreira U.

World J Urol. 2009 Jun;27(3):353-61. doi: 10.1007/s00345-009-0374-4. Epub 2009 Feb 13. Review.

PMID:
19214530
14.

Toll-like receptor expression in normal ovary and ovarian tumors.

Zhou M, McFarland-Mancini MM, Funk HM, Husseinzadeh N, Mounajjed T, Drew AF.

Cancer Immunol Immunother. 2009 Sep;58(9):1375-85. doi: 10.1007/s00262-008-0650-y. Epub 2009 Jan 31.

PMID:
19184006
15.

Toll-like receptor 2 mediates invasion via activating NF-kappaB in MDA-MB-231 breast cancer cells.

Xie W, Wang Y, Huang Y, Yang H, Wang J, Hu Z.

Biochem Biophys Res Commun. 2009 Feb 20;379(4):1027-32. doi: 10.1016/j.bbrc.2009.01.009. Epub 2009 Jan 12.

PMID:
19141294
16.

Toll like receptor - potential drug targets in infectious disease.

Erard F, Ryffel B.

Infect Disord Drug Targets. 2008 Dec;8(4):221-31. Review.

PMID:
19075797
17.

Toll-like receptors and cancer.

Rakoff-Nahoum S, Medzhitov R.

Nat Rev Cancer. 2009 Jan;9(1):57-63. doi: 10.1038/nrc2541. Epub 2008 Dec 4. Review.

PMID:
19052556
18.

Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors.

Goto Y, Arigami T, Kitago M, Nguyen SL, Narita N, Ferrone S, Morton DL, Irie RF, Hoon DS.

Mol Cancer Ther. 2008 Nov;7(11):3642-53. doi: 10.1158/1535-7163.MCT-08-0582.

19.

Cancer-related inflammation.

Mantovani A, Allavena P, Sica A, Balkwill F.

Nature. 2008 Jul 24;454(7203):436-44. doi: 10.1038/nature07205. Review.

PMID:
18650914
20.

Role of neutrophils in BCG immunotherapy for bladder cancer.

Simons MP, O'Donnell MA, Griffith TS.

Urol Oncol. 2008 Jul-Aug;26(4):341-5. doi: 10.1016/j.urolonc.2007.11.031. Review.

Supplemental Content

Support Center